3,883
edits
Changes
MDS, MDS/MPN and MPN Tables: Recurrent Genomic Alterations Detected by Chromosomal Microarray (view source)
Revision as of 16:54, 30 April 2020
, 16:54, 30 April 2020no edit summary
'''Table 1.''' Evidence for the clinical utility of chromosomal microarray testing (CMA) in myeloid disorders excluding acute myeloid leukemia
'''Table 1 - Evidence for the Clinical Utility of Chromosomal Microarray (CMA) Testing in Myeloid Disorders Excluding Acute Myeloid Leukemia (Literature Review).''' Table derived from Kanagal-Shawanna et al., 2018 [PMID 30377088] with permission from Cancer Genetics.
{| class="wikitable"
{| class="wikitable"
|'''Disease'''
|'''Disease'''
∗Recurrent indicates recurrent aberration with no established prognostic significance
∗Recurrent indicates recurrent aberration with no established prognostic significance
'''Table 2.''' A comprehensive list of CNAs and CN-LOH of known or likely clinical significance in MDS detected by CMA testing
'''Table 2 -''' '''A Comprehensive List of Copy Number Aberrations and CN-LOH of Known or Likely Clinical Significance in MDS Detected by CMA Testing (Literature Review).''' Table derived from Kanagal-Shawanna et al., 2018 [PMID 30377088] with permission from Cancer Genetics.
{| class="wikitable"
{| class="wikitable"
|'''Chromosome'''
|'''Chromosome'''
∗∗∗ Potential marker for responsiveness to hypomethylating agents or DNA methyltransferase inhibitors (Bejar et al., Blood 124:2705–12, 2014;Traina et al., Leukemia 28:78–87, 2014).
∗∗∗ Potential marker for responsiveness to hypomethylating agents or DNA methyltransferase inhibitors (Bejar et al., Blood 124:2705–12, 2014;Traina et al., Leukemia 28:78–87, 2014).
'''Table 3. ''' A comprehensive list of CNAs and CN-LOH of known or likely clinical significance in MDS/MPN detected by CMA testing
'''Table 3''' '''-''' '''A Comprehensive List of Copy Number Aberrations and CN-LOH of Known or Likely Clinical Significance in MDS/MPN Detected by CMA Testing (Literature Review).''' Table derived from Kanagal-Shawanna et al., 2018 [PMID 30377088] with permission from Cancer Genetics.
{| class="wikitable"
{| class="wikitable"
|'''Chromosome'''
|'''Chromosome'''
∗∗∗ Haploinsufficiency of 17p as part of an isolated isochromosome may be a distinct disease entity with further increased risk of AML progression relative to 17p loss in a complex karyotype.
∗∗∗ Haploinsufficiency of 17p as part of an isolated isochromosome may be a distinct disease entity with further increased risk of AML progression relative to 17p loss in a complex karyotype.
'''Table 4.''' A comprehensive list of CNAs and CN-LOH of known or likely clinical significance in MPN detected by CMA testing
'''Table 4''' '''-''' '''A Comprehensive List of Copy Number Aberrations and CN-LOH of Known or Likely Clinical Significance in MPN Detected by CMA Testing (Literature Review).''' Table derived from Kanagal-Shawanna et al., 2018 [PMID 30377088] with permission from Cancer Genetics.
{| class="wikitable"
{| class="wikitable"
|Chromosome
|Chromosome